OCUP vs. CLNN, HCWB, RMTI, AADI, GANX, XLO, IMRX, NBRV, SNSE, and BLRX
Should you be buying Ocuphire Pharma stock or one of its competitors? The main competitors of Ocuphire Pharma include Clene (CLNN), HCW Biologics (HCWB), Rockwell Medical (RMTI), Aadi Bioscience (AADI), Gain Therapeutics (GANX), Xilio Therapeutics (XLO), Immuneering (IMRX), Nabriva Therapeutics (NBRV), Sensei Biotherapeutics (SNSE), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical preparations" industry.
Clene (NASDAQ:CLNN) and Ocuphire Pharma (NASDAQ:OCUP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.
Clene received 24 more outperform votes than Ocuphire Pharma when rated by MarketBeat users. Likewise, 75.32% of users gave Clene an outperform vote while only 68.00% of users gave Ocuphire Pharma an outperform vote.
In the previous week, Ocuphire Pharma had 1 more articles in the media than Clene. MarketBeat recorded 19 mentions for Ocuphire Pharma and 18 mentions for Clene. Ocuphire Pharma's average media sentiment score of 0.48 beat Clene's score of -0.20 indicating that Clene is being referred to more favorably in the media.
Ocuphire Pharma has higher revenue and earnings than Clene. Ocuphire Pharma is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.
Clene presently has a consensus target price of $6.50, indicating a potential upside of 1,585.68%. Ocuphire Pharma has a consensus target price of $18.75, indicating a potential upside of 980.69%. Given Ocuphire Pharma's higher possible upside, equities analysts plainly believe Clene is more favorable than Ocuphire Pharma.
23.3% of Clene shares are held by institutional investors. Comparatively, 15.0% of Ocuphire Pharma shares are held by institutional investors. 25.1% of Clene shares are held by company insiders. Comparatively, 8.7% of Ocuphire Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Clene has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Ocuphire Pharma has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500.
Ocuphire Pharma has a net margin of -59.44% compared to Ocuphire Pharma's net margin of -7,873.23%. Clene's return on equity of -24.57% beat Ocuphire Pharma's return on equity.
Summary
Clene beats Ocuphire Pharma on 10 of the 18 factors compared between the two stocks.
Get Ocuphire Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocuphire Pharma Competitors List
Related Companies and Tools
